Patient characteristics | |
---|---|
Sex (female/male) | 12/19 |
Age in years, median [range] | 67 [25–83] |
Height in meter, median [range] | 1.70 [1.52–1.83] |
Weight in kg, median [range] | 74 [48–116] |
Tumor type, n (%) | |
HCC | 19 (61.3%) |
No cirrhosis | 5 |
Proven cirrhosis | 14 |
NASH | 7 |
ASH | 4 |
HBV | 1 |
HCV | 1 |
Unknown etiology | 4 |
CRC | 6 (19.4%) |
NET | 3 (9.7%) |
Pancreas | 1 (3.2%) |
Breast | 1 (3.2%) |
Stomach | 1 (3.2%) |
Portal vein embolism, n | |
Patients with PVE | 2 |
Prior treatment, n (median months between last cycle and SIRT [min,max]) | |
Systemic treatment | 13 (1.0 [0.3, 15.2]) |
Anti-angiogenic ⋆ | 6 (9.7 [0.5, 16.6]) |
Anti-angiogenic (directly before SIRT) | 3 (0.9 [0.5, 15.2]) |
Anti-angiogenic (not directly before SIRT) | 3 (14.1 [5.3, 16.6]) |
Non anti-angiogenic ⋆⋆ | 7 (0.7 [0.3, 13.4]) |
RFA/MWA | 6 (13.8 [3.5, 31.0]) |
TACE | 4 (8.3 [4.1, 48.3]) |
Resection | 3 (14.4 [1.3, 41.9]) |
Volumes from prescription sheet (ml), median [range] | |
Total liver | 1741 [789–4122] |
Non-tumoral liver | 1538 [682–2942] |
Tumor | 134 [0–2785] |
Tumor burden | |
Median [range], % | 8.8 [0.0–67.6] |
< 5%, n (%) | 10 (32%) |
5–10%, n (%) | 8 (26%) |
10–25%, n (%) | 8 (26%) |
25-50%,n (%) | 3 (10%) |
> 50%,n (%) | 2 (6%) |
MAA work-up information | |
Lung shunt fraction (%) | 8.0 [0.0–13.9] |
Time from treatment in days, median [range] | 18 [9–46] |
Prescription method | |
Non-compartmental partition model, n (%) | 16 (52%) |
Compartmental partition model, n (%) | 14 (45%) |
Mixture of models, n (%) | 1 (3%) |
Treatment strategy | |
Whole liver, n (%) | 2 (6%) |
Bi-lobar, n (%) | 15 (48%) |
Mono-lobar, n (%) | 10 (32%) |
Selective (3 segments), n (%) | 3 (10%) |
Selective (4 segments), n (%) | 1 (3%) |
Prescribed activity | |
Total administered activity (GBq) [range] | 1.527 [0.383–3.700] |
Number of analyzed tumors (bigger than 5 ml) | |
Patients with 1 tumor, n (%) | 16 (52%) |
Patients with 2–3 tumors, n (%) | 11 (35%) |
Patients with more than 3 tumors, n (%) | 4 (13%) |
Analyzed LPTs information from prescription sheet | |
Total LPT (cc), median [range] | 1001 [57–3172] |
Non-tumoral liver (cc), median [range] | 849 [0–2268] |
Tumor (cc), median [range] | 67 [0, 2785] |
LPT to total liver ratio (%), median [range] | 54 [3–100] |
Tumor burden | |
Median [range], % | 9.4 [0.0–100.0] |
< 5%, n (%) | 16 (34%) |
5–10%, n (%) | 9 (19%) |
10–25%, n (%) | 11 (23%) |
25–50%, n (%) | 8 (17%) |
> 50%, n (%) | 3 (6%) |
Post-treatment image modality | |
PET/MR - PET/CT, n(%) | 28 (90%) – 3 (10%) |